Proceedings of the 1st EAI International Conference on Medical And Health Research, ICoMHER November 13-14th 2018, Padang, West Sumatera, Indonesia

Research Article

Evaluation of Oral Anticoagulant Use in Atrial Fibrillation Patients

Download21 downloads
  • @INPROCEEDINGS{10.4108/eai.13-11-2018.2283636,
        author={Gestina  Aliska and Erlina  Rustam and Elly  Usman and Ivan Mahendra Raditya},
        title={Evaluation of Oral Anticoagulant Use in Atrial Fibrillation Patients},
        proceedings={Proceedings of the 1st EAI International Conference on Medical And Health Research, ICoMHER November 13-14th 2018, Padang, West Sumatera, Indonesia},
        publisher={EAI},
        proceedings_a={ICOMHER},
        year={2019},
        month={5},
        keywords={anticoagulants bleeding warfarin},
        doi={10.4108/eai.13-11-2018.2283636}
    }
    
  • Gestina Aliska
    Erlina Rustam
    Elly Usman
    Ivan Mahendra Raditya
    Year: 2019
    Evaluation of Oral Anticoagulant Use in Atrial Fibrillation Patients
    ICOMHER
    EAI
    DOI: 10.4108/eai.13-11-2018.2283636
Gestina Aliska1,*, Erlina Rustam1, Elly Usman1, Ivan Mahendra Raditya1
  • 1: Department of Pharmacology and Therapeutic, Faculty of Medicine, Andalas University
*Contact email: aliska@med.unand.ac.id

Abstract

Oral anticoagulant (OAC) is used for thromboembolic prevention in atrial fibrillation (AF) patients. This study aim to observe the use of OAC in AF patients in a tertiary Hospital. We enrolled all patients with complete data of medical record. The data of the use of OAC in AF patients is taken from patients that was hospitalized in Cardiology ward during January 2015-August 2016. Patients were given OAC during hospitalization. Sixty three patients with atrial fibrillation were analysed in this study. Incidence of valvular disease was higher than non-valvular atrial fibrillation (65% vs 35% patients). Most of the patients was women (67.4%). Warfarin as oral anticoagulant for thromboembolic prevention was still more popular than dabigatran (61.8% vs 34.2%). Almost of patients had low HAS-BLED score. The intrahospital bleeding occured in 6% of all patients given warfarin. Warfarin is still used as a mainstay therapy in AF patients for thromboembolic prevention. Bleeding rate due to warfarin use for hospitalized patients was rare